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ABSTRACT
Almost forty years ago the relationship between the circulating neutrophil count and the risk of
pyogenic infection was established. Since that time, through the vehicle of clinical trials, much has been
learnt about the etiologies, risk factors, pathogenesis, and natural history of ﬁrst and subsequent febrile
neutropenic episodes. Reﬁnements to the empirical antibacterial management has reduced infection-
related mortality to less than 10 percent. Algorithmic approaches to persistent fever in the setting of
severe neutropenia have been developed. Circumstances wherein preventative strategies are most
efﬁcacious have been deﬁned. Clinicians have learned that neutropenic patients comprise a
heterogeneous population that does not encounter the same risks for infection-related morbidity and
mortality. Tailored stratiﬁed approaches to management of the febrile neutropenic patient have been
developed that are safe and cost-effective.
Keywords: cancer, febrile neutropenic episodes, natural history, neutropenia, pathogenesis, prophy-
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INTRODUCTION
The standard of practice for the management of
febrile neutropenic cancer patients includes a
rapid clinical evaluation to identify a clinical focus
of infection and a pathogen, in-hospital intraven-
ous administration of broad-spectrum antibacte-
rial therapy, and a strategy to monitor the patient
for medical complications [1–4]. This approach has
been based upon the recognition that such patients
with invasive Gram-negative bacillary infection
have a very high mortality rate unless treated
without delay [5]. However, it is recognised that
not all neutropenic patients have the same risks for
fever and infection, and not all febrile neutropenic
episodes have the same mortality and morbidity.
A better understanding of the pathogenesis of
infection in neutropenic patients has permitted
investigators to develop more rational approaches
to this heterogeneous problem.
A SHORT HISTORY OF FEVER IN
NEUTROPENIA
Over the last 40 years, much has been learned
about infections in neutropenic cancer patients and
the management thereof. The seminal work of
Bodey et al. initially described the relationship
between the absolute neutrophil count and the risk
for pyogenic infection [6,7]. The importance of
prompt initiation of broad-spectrum combination
antibacterial therapy with carbenicillin and
gentamicin for preventing resistance, broadening
the spectrumof antimicrobial activity andpotential
synergy was described by Schimpff et al. in 1971
[8]. These same investigators went on to describe
the relationship between mucosal colonisation by
nosocomially-acquired bacterial pathogens and
invasive infection in patients with acute myeloid
leukaemia [9]. The question of the duration
of broad-spectrum antibacterial therapy was
addressed in a study from the National Cancer
Institute, wherein persistently neutropenic recipi-
ents initially responsive to empirical antibacterial
therapy had a 41% rate of recrudescence unless
the antibacterial regimen was continued until
Corresponding author and reprint requests: E. J. Bow, Health
Sciences Centre, Rm GD600, 820 Sherbrook Street, Winnipeg,
Manitoba, Canada R3A 1R9
E-mail: ebow@hsc.mb.ca
 2005 Copyright by the European Society of Clinical Microbiology and Infectious Diseases
neutrophil recovery [10]. Those same investigators
also deﬁned the role for empirical antifungal
therapy among persistently febrile neutropenic
patients unresponsive to broad-spectrum antibac-
terial therapy [11]. The value of broad-spectrum
aminoglycoside-based combination empirical anti-
bacterial therapy has been recently questioned
[12,13]. While the value of neutrophil transfusion
therapyhas been controversial [14,15], it has shown
promise under speciﬁed conditions [16]. Haema-
topoietic growth factors have not been shown to be
beneﬁcial in the management of febrile neutropen-
ic patients [17] and are not recommended for this
use [18]. Prevention of pyogenic bacterial infec-
tions in high-risk patients by the administration of
prophylactic oral antimicrobial agents has been
widely studied with mixed success, largely related
to the changing epidemiology of bacterial infec-
tions towards Gram-positive infections and the
prevalence of resistance of pathogens targeted by
the chemoprophylaxis strategy [19–22]. There has
been an increased focus on strategies of prevention
[23–25] andmanagement [26,27] of invasive fungal
infections based upon standardized deﬁnitions
[28] in deﬁnedgroups of high-risk patients. Finally,
the ability to stratify febrile neutropenic patients by
risk for signiﬁcant medical complications has
allowed for the identiﬁcation of groups of patients
for whom outpatient management strategies are
safe and effective [29–31].
PATHOGENESIS OF FEBRILE
NEUTROPENIC EPISODES
The timing of the ﬁrst febrile neutropenic episode
in patients receiving a given cycle of cytotoxic
therapy is correlated with the nadir of the neu-
trophil count and with the integumental damage
due to the effects of the cytotoxic regimen on the
intestinal mucosal epithelium. The median time
for onset of the febrile neutropenic episode is day
12 from the ﬁrst day of the current cycle of
cytotoxic therapy [32].
Cytotoxic therapy-induced intestinal epithelial
damage is an important component in the path-
ogenesis of ﬁrst and subsequent fevers in neu-
tropenic patients [33]. Microorganisms colonising
damaged mucosal surface may then undergo
translocation and subsequent tissue invasion [9].
Investigators have reported relationships between
the administration of cytotoxic agents such as
high-dose cytarabine and oral mucositis and
subsequent bloodstream infections due to resi-
dent periodontal microﬂora such as the viridans
group streptococci [34]. Sonis et al. reported the
relationship between the severity of oropharyn-
geal mucositis, as measured on a standardised
scale, and the incidence of febrile events, docu-
mented infections, days of hospitalisation and
costs in haematopoietic stem cell transplant recip-
ients [35]. The timing of maximal mucositis scores
correlates independently with the neutrophil
nadir [36–38].
The infections reported in febrile neutropenic
patients have been classiﬁed as ‘unexplained
fevers’ if neither a pathogen nor a focus of
infection has been identiﬁed, as ‘clinically docu-
mented’ if only a clinical focus is identiﬁed, and as
‘microbiologically documented’ if both a patho-
gen and a site of infection are identiﬁed [39]. The
gastrointestinal tract, in particular the oropharynx
and periodontium, is now the most common
source of infection identiﬁed in febrile neutro-
penic patients [40]. The bloodstream is the next
most common site wherein Gram-positive micro-
organisms are the pathogens isolated in almost
two-thirds of cases [40]. The use of ﬂuroquino-
lone-based antibacterial chemoprophylaxis strat-
egies has reduced the risk of Gram-negative
infection under the epidemiological circum-
stances wherein the prevalence of ﬂuoroquino-
lone resistance among aerobic Gram-negative
bacilli is less than 3–5% [19–22]. In decreasing
order, the skin (predominantly the indwelling
central venous catheter site), lower respiratory
tree and urinary tract are the next most common
sites of infection.
Cytotoxic therapy-induced myelosuppression
and the associated risk of infection vary with the
dose-intensity of the chemotherapeutic regimen
[41]. Regimens based upon cytarabine plus an
anthracycline or high-dose cytarabine adminis-
tered for remission–induction therapy for acute
myeloid leukaemia are typically associated with
periods of severe neutropenia (absolute neutro-
phil count < 0.5 · 109 ⁄L) lasting 10–14 days or
more before recovery of the absolute neutrophil
count to > 0.5 · 109 ⁄L. The risk of opportunistic
infection is directly related to the duration of
severe neutropenia [42]. In contrast, the expected
duration of severe neutropenia among patients
receiving cyclophosphamide, doxorubicin, vincr-
istine and prednisone for non-Hodgkin’s lym-
phoma is only 3–5 days [43]. Seventy to 90 per
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cent of patients undergoing remission–induction
chemotherapy for acute myeloid leukaemia will
experience one or more febrile episodes during
the neutropenic period. Up to 98% of patients
undergoing high-dose chemotherapy with hema-
topoietic stem-cell rescue experience febrile neu-
tropenic episodes during the pre-engraftment
neutropenic phase [44]. In contrast, in speciﬁc
circumstances associated with intensive cytotoxic
therapy such as non-myeloablative allogeneic
haematopoietic stem-cell transplants or adminis-
tration of cyclophosphamide, doxorubicin, vincr-
istine and prednisone in elderly patients for
diffuse large cell lymphoma, the duration of
severe neutropenia may be shorter; however, the
incidence of febrile neutropenic episodes has
remained relatively high, ranging from 35%
(Hagen CID 2003) to 45% [44]. In general, the
incidence of febrile neutropenic episodes among
patients with non-Hodgkin’s lymphoma is lower,
with reported ranges of 10–20% [41,47–48] and
with the greatest risk occurringwithin the ﬁrst two
cycles of chemotherapy (47). Other factors includ-
ing age ‡65 years, tumour burden, receipt of
average relative dose-intensity of chemotherapy
of ‡85%, absolute neutrophil count of £1.5 · 109/
L at diagnosis, baseline serum albumin of
£35 grams/L at diagnosis, and the presence of
additional medical co-morbidities at baseline have
been associated with increased risk for febrile
neutropenic episodes among patients receiving
cyclophosphamide, doxorubicin, vincristine and
prednisone for large B-cell lymphoma(48;49)
despite the relatively short duration of severe
neutropenia.
STRATIFICATION OF FEBRILE
NEUTROPENIC PATIENTS BY RISK
Febrile neutropenic cancer patients form a very
heterogeneous population with respect to the
risks for complications that require prolonged
hospitalisation [50]. Such complications involve
the requirement for critical care services, to cope
with haemodynamic instability, hypotension, and
respiratory insufﬁciency; symptom control of
pain, nausea, vomiting, and diarrhoea; altered
mental status and delirium; reduced performance
status; haemorrhage requiring blood product
transfusion; cardiac dysrhythmia requiring mon-
itoring and treatment; and changes in renal func-
tion requiring intervention and treatment
modiﬁcations. Factors present at the onset of the
febrile neutropenic episode can be identiﬁed to
assign patients a high- or low-risk probability for
these complications [51–55]. Such approaches
have been used to identify patients appropriate
for oral antibacterial therapy [56–59] administered
on an outpatient basis [30,59–66].
The expectation for response, deﬁned by defer-
vescence, varies with the risk group. The median
time-to-defervescence for high-risk patients treat-
ed with appropriate empirical antibacterial regi-
mens is of the order of 5 days [32,40,67–69]. In
contrast, the expected time-to-defervescence
among low-risk patients has been of the order of
2–3 days [57,58]. Febrile neutropenic patients who
do not promptly defervesce are often targets for
inappropriate early regimen modiﬁcation [70],
particularly with glycopeptide antibiotics, the
value of which has been recently disputed [71].
The major indications for empirical antibiotic
regimen modiﬁcation before the median expected
time-to-defervescence include documented pro-
gression of signs and symptoms of infection, the
pathogen resistant to the initial empirical regi-
men, and regimen-related toxicity. Premature
modiﬁcation of the empirical regimen adds
potential toxicity and cost to the management
plan.
IMPACT OF ANTIBACTERIAL
CHEMOPROPHYLAXIS STRATEGIES
IN NEUTROPENIC CANCER
PATIENTS
Effective antibacterial chemoprophylaxis strat-
egies should reduce the incidence of febrile
episodes, reduce the incidence of documented
Gram-positive and Gram-negative infections,
reduce infection-related mortality, be tolerable,
and result in a signiﬁcant modiﬁcation of physi-
cian prescribing behaviour.
Patients receiving ﬂuoroquinolone-based anti-
bacterial prophylaxis are more likely to develop
invasive infection due to Gram-positive bacteria,
including coagulase-negative staphylococci and
viridans group streptococci [72], unless supple-
mented by augmented Gram-positive coverage
[22,73]. Even without the use of ﬂuoroquinolone-
based prophylaxis, the incidence of invasive
Gram-positive infections has demonstrably in-
creased [74]. Accordingly, empirical therapy with
agents such as piperacillin–tazobactam or
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meropenem, which are active against the viridans
group streptococci, is appropriate. Addition of
glycopeptides should be reserved for patients in
whom coagulase-negative staphylococcal blood-
stream infections are demonstrated [3,71,75]. Such
an approach has not been associated with excess
patient morbidity or mortality [71,75].
Arguments against the use of ﬂuoroquinolone-
based chemoprophylaxis include selection for
Gram-positive infections, the inability in clinical
trials to demonstrate clinically signiﬁcant reduc-
tions in the overall incidence of fever or reduc-
tions in overall mortality, the risk of selecting for
resistant pathogens, the potential for masking
documented infections, and promotion of fungal
colonisation with possible increase in the risk for
invasive fungal infections. In contrast, the argu-
ments favouring prophylaxis include statistically
signiﬁcant reductions in the incidence of fever
[20,21], reductions in the incidence of Gram-
negative infections [19–21], and the potential for
both reducing the need for broad Gram-negative
coverage in febrile neutropenic episodes and
changing physician prescribing behaviour
[32,76,77]. Overall, clinical trials have demonstrat-
ed that ﬂuoroquinolone-based antibacterial pro-
phylaxis does consistently reduce the risk of
Gram-negative and Gram-positive infections, if
supplemented in the latter case. Fluoroquinolone-
based prophylaxis does not eliminate fever or the
need for empirical antibacterial therapy, nor does
it reduce episode-related mortality or modify
physician prescribing behaviour, as related to
empirical therapy.
The initial treatment of febrile neutropenic
episodes in patients receiving ﬂuoroquinolone
prophylaxis in an environment with a low pre-
valence of Gram-negative ﬂuoroquinolone resist-
ance should be according to the current published
guidelines [1–4]; however, such patients who
continue the ﬂuoroquinolone prophylaxis may
be candidates for early discontinuance of Gram-
negative coverage in favour of antimicrobial
therapy targeting Gram-positive pathogens [33].
This remains an area for further clinical trial-
based research.
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